Several medical societies supported extending Medicare coverage for TAVR to patients with asymptomatic aortic stenosis, but ...

Edwards pushes CMS to expand Medicare TAVR coverage to asymptomatic patients, sparking controversy among physicians over ...

Please provide your email address to receive an email when new articles are posted on . At 5 years, there was no difference in death or disabling stroke between transcatheter aortic valve replacement ...

Please provide your email address to receive an email when new articles are posted on . The RHEIA trial included enrolled-only women randomly assigned to transcatheter vs. surgical aortic valve ...

Of the two heart valve surgeries Janice Smith has had at OhioHealth Mansfield Hospital, the second was much easier for her. "I had a good experience both times," the 86-year-old said. "It's just that ...

CHICAGO — Five years after treatment, patients with severe aortic stenosis had comparable rates of all-cause mortality or disabling stroke, whether they received transcatheter aortic valve replacement ...

High-risk surgical patients with severe aortic stenosis who underwent a transcatheter aortic valve replacement experienced higher one-year survival rates than patients who underwent traditional ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...

WASHINGTON, DC — New European registry data on transcatheter aortic-valve replacement (TAVR) in patients at lower surgical risk than those studied in the pivotal randomized trials offers the ...

Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.

Medtronic’s investment is contingent on Anteris completing a proposed $200 million public stock offering.